

Literatura ACTA MEDICINAE 1/2018 Biologická léčba

- 2 **Novinky v léčbě mnohočetného myelomu v roce 2017**
prof. MUDr. Ivan Špička, CSc. I. interní klinika, klinika hematonekologie, LF UK a VFN, Praha
- 2 **CAR T lymfocyty v léčbě akutní leukemie**
prof. MUDr. Petr Cetkovský, Ph.D., MBA Ústav hematologie a krevní transfuze, Praha
- 2 **Novinky v léčbě chronické lymfocytární leukemie**
MUDr. Stanislava Hrobková | prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno
- 2 **Nové možnosti snížení rizika hemolýzy u imunoglobulinových přípravků**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
prof. MUDr. Jiřina Bartůňková, DrSc. Ústav imunologie 2. LF UK a FN v Motole, Praha
- 3 **Emicizumab v léčbě hemofilie A**
MUDr. Peter Salaj Centrum pro trombózu a hemostázu, ÚHKT, Praha
- 3 **Novinky v cílené léčbě karcinomu prsu**
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň
- 3 **Biologická léčba karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha
- 3 **Biologická terapie karcinomu ovaria**
MUDr. Zdeněk Adamík, Ph.D. | MUDr. Soňa Krupková
Gynekologicko-porodnické oddělení, Krajská nemocnice T. Bati, a. s., Univerzita Tomáše Bati ve Zlíně
- 4 **Léčba metastatického karcinomu ledviny**
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 4 **Současné možnosti systémové léčby metastatického renálního karcinomu**
MUDr. Ivo Kocák, Ph.D. | doc. MUDr. Ilona Kocáková, Ph.D.
Klinika komplexní onkologické péče Masarykova onkologického ústavu a LF MU, Brno
- 4 **Význam biomarkerů pro léčbu anti-VEGF inhibitory a její účinnost u metastatického kolorektálního karcinomu**
MUDr. Zdeněk Linke Onkologická klinika FN v Motole, Praha
- 4 **Monoklonální protilátky anti-PD1 a anti-PD-L1 v léčbě solidních nádorů**
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
- 5 **Metastazující melanom: možné léčebné strategie**
MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika 1. LF UK a VFN, Praha
- 5 **Minimalizace rizik spojených s biologickou léčbou roztroušené sklerózy**
MUDr. Radek Ampapa Centrum pro léčbu demyelinizačních onemocnění, Neurologické oddělení Nemocnice Jihlava
- 5 **Biologická léčba v neurologii**
doc. MUDr. Martin Vališ, Ph.D. | MUDr. Zbyšek Pavelek Neurologická klinika LF a FN Hradec Králové
- 6 **Léčba axiálních spondyloartritid k cíli (koncept T2T)**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 6 **Riziko nádorové choroby při léčbě konvenčními, cílenými a biologickými DMARDs u pacientů s revmatoidní artritidou**
MUDr. Šárka Forejtová Revmatologický ústav, Praha
- 7 **Subkutánní tocilizumab v terapii revmatoidní artritidy**
MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 8 **Reslizumab – nová zbraň v boji s těžkým refrakterním eozinofilním astmatem**
MUDr. Vratislav Sedlák, Ph.D. Plicní klinika FN Hradec Králové a LF UK, Hradec Králové
- 8 **Studie I-SPY 2: patologická kompletní odpověď v léčbě karcinomu prsu predikuje přežití bez relapsu a bez distanční recidivy**
MUDr. Iveta Kolářová, Ph.D. | doc. MUDr. Jaroslav Vaňásek, CSc. | MUDr. Aleš Hlávka
Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o.
MUDr. Jana Mergancová Chirurgická klinika, Nemocnice Pardubického kraje, a. s., Pardubická nemocnice

Novinky v léčbě mnohočetného myelomu v roce 2017

prof. MUDr. Ivan Špička, CSc. I. interní klinika, klinika hematologie, LF UK a VFN, Praha

- Gay, F. – Engelhardt, M. – Terpos, E., et al.: From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. *Haematologica*, 2018, 103, s. 197–211, doi: 10.3324/haematol.2017.174573, Epub 7. 12. 2017.
- Benboubker, L. – Dimopoulos, M. A. – Dispenzieri, A., et al.: FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*, 2014, 371, s. 906–917, doi: 10.1056/NEJMoa1402551.
- Dimopoulos, M. A. – Stewart, A. K. – Masszi, T. – Špička, I., et al.: Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. *Br J Haematol*, 2017, 177, s. 404–413, doi: 10.1111/bjh.14549, Epub 17. 2. 2017.
- Dimopoulos, M. A. – Stewart, A. K. – Masszi, T. – Špička, I., et al.: Carfilzomib-lenalidomide-dexamethasone and lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. *Blood Cancer J*, 2017, 7, e554, doi: 10.1038/bcj.2017.31.
- Siegel, D. S. – Dimopoulos, M. A. – Ludwig, H., et al.: Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma. *Clin Oncol*, 2018, doi: 10.1200/JCO.2017.76.5032.
- Chim, C. S. – Kumar, S. K. – Orlowski, R. Z., et al.: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. *Leukemia*, 2018, 32, s. 252–262, doi: 10.1038/leu.2017.329, Epub 16. 11. 2017.
- Avet-Loiseau, H. – Bahlis, N. J. – Chng, W. J., et al.: Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. *Blood*, 2017, 130, s. 2610–2618, doi: 10.1182/blood-2017-06-791228, Epub 20. 10. 2017.
- Dimopoulos, M. A. – Oriol, A. – Nahi, H., et al.; Moreau POLLUX Investigators: Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*, 2016, 375, s. 1319–1331.
- Palumbo, A. – Chanan-Khan, A. – Weisel, K., et al.; CASTOR Investigators: Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med*, 2016, 375, s. 754–766, doi: 10.1056/NEJMoa1606038.
- Mateos, M. V. – Dimopoulos, M. A. – Cavo, M., et al.; ALCYON Trial Investigators: Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med*, 2012, 12. 2017, doi: 10.1056/NEJMoa1714678.
- Richardson, P. G. – Attal, M. – Campana, F., et al.: Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. *Future Oncol*, 2017, 12. 2017, doi: 10.2217/fo-2017-0616.
- Martin, T. – Baz, R. – Benson, D. M., et al.: A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. *Blood*, 2017, 129, s. 3294–3303, doi: 10.1182/blood-2016-09-740787, Epub 8. 5. 2017.
- Badros, A. – Hyjek, E. – Ma, N., et al.: Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. *Blood*, 2017, 130, s. 1189–1197, doi: 10.1182/blood-2017-06-791228, Epub 20. 10. 2017.
- Ali, S. A. – Shi, V. – Maric, I., et al.: T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. *Blood*, 2016, 128, s. 1688–1700.
- Alonso-Álvarez, S. – Pardo, E. – Sánchez-Nieto, D., et al.: Plitidepsin: design, development, and potential place in therapy. *Drug Des Devel Ther*, 2017, 11, s. 253–264, doi: 10.2147/DDDT.S94165, eCollection 2017, recenze.
- Špička, I. – Ocio, E. – Oakervee, H. E., et al.: Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. *ASH 2017*.
- Vogl, D. T. – Dingli, D. – Cornell, R. F., et al.: Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. *J Clin Oncol*, 2017, 35, s. 1588–1599, doi: 10.1200/JCO.2017.75.5207.

CAR T lymfocyty v léčbě akutní leukemie

prof. MUDr. Petr Cetkovský, Ph.D., MBA Ústav hematologie a krevní transfuze, Praha

- Gross, G., et al.: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptor with antibody-type specificity. *Proc Natl Acad Sci USA*, 1989, 86, s. 10024–10028.
- Ruella, M. – June, C. H.: Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. *Curr Hematol Malig Rep*, 2016, 11, s. 368–384.
- Maus, M. V., et al.: Antibody-modified T-cells: CARs take the front seat for hematological malignancies. *Blood*, 2014, 123, s. 2625–2635.
- Lee, D. W., et al.: T cells expressing CD 19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose escalation trial. *Lancet*, 2005, 385, s. 517–528.
- Chabannon, C., et al.: CAR-T cells: the narrow path between hope and bankruptcy? *Bone Marrow Transplant*, 2017, 52, s. 1588–1589.

Novinky v léčbě chronické lymfocytární leukemie

MUDr. Stanislava Hrobková | prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika LF MU a FN Brno

- Hallek, M.: Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. *Am J Hematol*, 2017, 92, s. 946–965.
- Eichhorst, B. – Robak, T. – Montserrat, E., et al.: Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up dagger. *Ann Oncol*, 2015, 26, suppl. 5, s. v78–v84.
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. *The Lancet Oncology*, 17, s. 779–790.
- Burger, J. A. – Buggy, J. J.: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). *Leuk Lymphoma*, 2013, 54, s. 2385–2391.
- Byrd, J. C. – Brown, J. R. – O'Brien, S., et al.: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*, 2014, 371, s. 213–223.
- Byrd, J. C. – Hillmen, P. – O'Brien, S. M., et al.: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. *J Clin Oncol*, 2017, 35, suppl., abstrakt 7510.
- Woyach, J. A. – Furman, R. R. – Liu, T.-M., et al.: Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med*, 2014, 370, s. 2286–2294.
- Maffei, R. – Fiorcari, S. – Martinelli, S., et al.: Targeting neoplastic B cells and harnessing microenvironment: The "double face" of ibrutinib and idelalisib. *J Hematol Oncol*, 2015, 8, s. 60.
- Furman, R. R., et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2014, 370, s. 997–1007.
- Imbruvica (ibrutinib). Souhrn údajů o přípravku (SPC). Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf, vyhledáno 4. 2. 2018.
- Zydelig (idelalisib). Souhrn údajů o přípravku (SPC). Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003843/WC500175377.pdf, vyhledáno 4. 2. 2018.
- Byrd, J. C., et al.: Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2016, 374, s. 323–332.
- Robak, P. – Robak, T.: Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. *Expert Opinion on Investigational Drugs*, 2017, 26, s. 1249–1265.
- Seymour, J. F. – Davids, M. S. – Pagel, J. M., et al.: ABT-199 (GDC-0199) in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: high response rates among patients with high risk disease feature including unmutated IGHV [EHA abstrakt S702]. *Haematologica*, 2014, 99, suppl. 1.
- Seymour, J. F. – Ma, S. – Brander, D. M., et al.: Venetoclax plus rituximab in relapse or refractory chronic lymphocytic leukaemia: a phase 1b study. *Lancet Oncol*, 2017, 18, s. 230–240.
- Venclyxto (venetoclax). Souhrn údajů o přípravku (SPC). Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/004106/WC500218800.pdf, vyhledáno 4. 2. 2018.
- Maude, S. L. – Teachey, D. T. – Porter, D. L., et al.: CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Blood*, 2015, s. 4017–4023.
- Maude, S. – Barrett, D. M.: Current status of chimeric antigen receptor therapy for hematological malignancies. *Br J Haematol*, 2016, 172, s. 11–22.

Nové možnosti snížení rizika hemolýzy u imunoglobulinových přípravků

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha,

prof. MUDr. Jiřina Bartůňková, DrSc. Ústav imunologie 2. LF UK a FN v Motole, Praha

- Kahwaji, J., et al.: Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. *Clin J Am Soc Nephrol*, 2009, 4, s. 1993–1997.
- Bellac, C. L., et al.: The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. *Transfusion*, 2015, 55, suppl. 2, S13–S22.
- CSL Behring. Data on File. Privigen Swiss Prescribing Information (anglický překlad).
- Romberg, V., et al.: Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products. *Transfusion*, 2015, 55, suppl. 2, S105–S109.
- Siani, B., et al.: Donor screening reduces the isoagglutinin titer in immunoglobulin products. *Transfusion*, 2015, 55, suppl. 2, S95–S97.
- Gerber, S., et al.: Reduction of isoagglutinin in intravenous immunoglobulin (IVIg) using specific immunoaffinity chromatography: large scale assessment. *Bio Drugs*, 2016, 30, s. 441–451.
- Hoefler, L., et al.: Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. *Transfusion*, 2015, 55, suppl. 2, S117–S121.
- Hubsch, A. P., et al.: Specific anti-A/B immunoaffinity chromatography step reduces isoagglutinin levels in an intravenous immunoglobulin product. 2016 AAAA Annual Meeting, Los Angeles, CA, poster.
- Shebl, A., et al.: Reduction of isoagglutinins in intravenous immunoglobulin by anti-A donor screening and spontaneous reporting rates of haemolytic reactions worldwide. 2016 INC PNS Meeting, Glasgow, Skotsko, poster.
- ENCEPP: Privigen use and haemolytic anaemia in adults and children and the Privigen safety profile in children with CIDP – an observational hospital-based cohort study in the US (Privigen PASS). Dostupné z: <http://www.encepp.eu/encepp/viewResource.htm?id=6515>, vyhledáno 1. 3. 2018.

Emicizumab v léčbě hemofilie A

MUDr. Peter Salaj Centrum pro trombózu a hemostázu, ÚHK, Praha

- 1 WFH: Guidelines for the management of haemophilia, 2012. Dostupné z: <http://www1.wfh.org/publications/files/pdf-1472.pdf>, vyhládko 12/2017.
- 2 Berntorp, E. – Shapiro, A. D.: Modern haemophilia care. *Lancet*, 2012, 370, s. 1447–1456.
- 3 Oldenburg, J., et al.: Emicizumab prophylaxis in hemophilia A with inhibitors. *NEJM*, 10. 7. 2017, DOI: 10.1056/NEJMoa1703068.
- 4 Young, G., et al.: HAVEN 2: efficacy, safety, and pharmacokinetics of once-weekly prophylactic emicizumab (ACE910) in pediatric patients (< 12 years) with hemophilia A with inhibitors: interim analysis of single-arm, multicenter, open-label, phase 3 study. ASH 2017, přednáška.
- 5 Klamroth, R.: A new era of treatment for patients with haemophilia A? *Hämostaseologie*, 2017, 3, s. 216–218.

Novinky v cílené léčbě karcinomu prsu

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

- 1 Rimawi, M. F. – Schiff, R. – Osborne, C. K.: Targeting HER2 for the treatment of breast cancer. *Annu Rev Med*, 2015, 66, s. 111–128.
- 2 Zanardi, E. – Bregni, G. – de Braud, F., et al.: Targeted combination therapies in breast cancer. *Semin Oncol*, 2015, 42, s. 887–895.
- 3 Moasser, M. M. – Krop, I. E.: The evolving landscape of HER2 targeting in breast cancer. *JAMA Oncol*, 2015, 1, s. 1154–1161.
- 4 Murphy, C. G. – Dickler, M. N.: Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. *Endocr Relat Cancer*, 2016, 23, s. R337–R352.
- 5 Fan, W. – Chang, J. – Fu, P.: Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. *Future Med Chem*, 2015, 7, s. 1511–1519.
- 6 Maximiano, S. – Magalhães, P. – Guerreiro, M. P., et al.: Trastuzumab in the treatment of breast cancer. *Bio Drugs*, 2016, 30, s. 75–86.
- 7 Higgins, M. J. – Baselga, J.: Targeted therapies for breast cancer. *J Clin Invest*, 2011, 121, s. 3797–3803.
- 8 Richard, S. – Finn, R. S. – Martin, M., et al.: Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*, 2016, 375, s. 1925–1936.
- 9 Cristofanilli, M. – Turner, N. C. – Bondarenko, I. R. J., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncology*, 2016, 17, s. 425–439.
- 10 Hortobagyi, G. N. – Stemmer, S. M. – Burris, H. A., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*, 2016, 375, s. 1738–1748.
- 11 Fasching, P. A. – Jerusalem, G. M. J. – Pivot, X., et al.: Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. *J Clin Oncol*, 2017, 34, suppl.
- 12 Dickler, M. N. – Tolane, S. M. – Rugo, H. S., et al.: MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. *Clin Cancer Res*, 2017, 23, s. 5218–5224.
- 13 George, W. – Sledge, Jr. G. W. – Toi, M., et al.: MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*, 2017, 35, s. 2875–2884.
- 14 Goetz, M. P. – Toi, M. – Campone, M., et al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*, 2017, 35, s. 3638–3646.

Biologická léčba karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha

- 1 Yu, H. A., et al.: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clin Cancer Res*, 2013, 19, s. 2240–2247.
- 2 Mok, T. S. – Wu, Y.-L. – Thongprasert, S., et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*, 2009, 361, s. 947–957.
- 3 Yang, C., et al.: Final overall survival results from a phase III, randomised, open-label, first-line study of gefitinib v carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). ESMO 2010, abstrakt LBA2.
- 4 Thress, K. S. – Paweletz, C. P. – Felip, E., et al.: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. *Nat Med*, 2015, 21, s. 560–562.
- 5 Zhou, C. – Wu, Y.-L. – Chen, G., et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*, 2011, 12, s. 735–742.
- 6 Rosell, R., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 239–246.
- 7 Yang, J. Ch. H. – Schuler, M. H. – Yamamoto, N., et al.: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, suppl., abstrakt LBA7500.
- 8 Park, K. – Tan, E. H., et al.: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 577–589.
- 9 Wu, Y. L. – Cheng, Y. – Zhou, X., et al.: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 1454–1466, doi: 10.1016/S1470-2045(17)30608-3, Epub 25. 9. 2017.
- 10 Yang, J. C., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort. Abstrakt 943, přednáška, prezentováno na 16. World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 11 Mitsudomi, T., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. Abstrakt 1406, přednáška, prezentováno na 16. World Conference on Lung Cancer, 6.–9. 9. 2015, Denver, CO.
- 12 Mok, T. S. – Wu, Y. L. – Ahn, M. J., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M positive lung cancer. *N Engl J Med*, 2017, 376, s. 629–640.
- 13 Soria, J.-Ch. – Ohe, Y. – Vansteenkiste, J., et al.: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 113–125, doi: 10.1056/NEJMoa1713137.
- 14 Thatcher, N. – Hirsch, F. R. – Luft, A. V., et al.: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncology*, 2015, 16, s. 763–774.
- 15 Kwak, E. L. – Bang, Y. – Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1697.
- 16 Mok, T. – Kim, D. W. – Solomon, B. J., et al.: First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). *J Clin Oncol*, 2014, 32, 15, suppl. 1, abstrakt 8002.
- 17 Shaw, A. T., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*, 2014, 371, s. 1963–1971.
- 18 Dong-Wan, K., et al.: Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. *J Clin Oncol*, 2014, 32, suppl., abstrakt 8003.
- 19 Song, Z. – Wang, M. – Zhang, A.: Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance [J]. *Acta Pharmaceutica Sinica B*, 2015, 5, s. 34–37.
- 20 Ajimizu, H. – Kim, Y. H. – Mishima, M.: Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. *Med Oncol*, 2015, 32, s. 477.
- 21 Gainor, J. F. – Sherman, C. A. – Willoughby, K., et al.: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. *J Thorac Oncol*, 2015, 10, s. 232–236.
- 22 Peters, S. – Camidge, R. – Shaw, A. T., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 829–838, doi: 10.1056/NEJMoa1704795.
- 23 Sandler, A., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *NEJM*, 2006, 355, s. 2542–2550.
- 24 Reck, M. – Kaiser, R. – Mellemegaard, A., et al.: LUME-Lung 1 Study Group: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. *Lancet Oncol*, 2014, 15, s. 143–155, doi: 10.1016/S1470-2045(13)70586-2, Epub 9. 1. 2014.
- 25 Garon, E. B. – Ciuleanu, T. E. – Arrieta, O., et al.: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet*, 2014, 384, s. 665–673.
- 26 Seto, T. – Kato, T. – Nishio, M., et al.: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncol*, 2014, dostupné z: [http://dx.doi.org/10.1016/S1470-2045\(14\)70381-X](http://dx.doi.org/10.1016/S1470-2045(14)70381-X), publikováno online 28. 8. 2014.
- 27 Rosell, R. – Dafni, U. – Felip, E., et al.: Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med*, 2017, 5, s. 435–444, doi: 10.1016/S2213-2600(17)30129-7, Epub 10. 4. 2017.
- 28 Planchard, D. – Besse, B. – Groen, H. J. M., et al.: An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928). *J Clin Oncol*, 2016, 34, suppl., abstrakt 107.

Biologická terapie karcinomu ovaria

MUDr. Zdeněk Adamík, Ph.D. | MUDr. Soňa Krupková

Gynekologicko-porodnické oddělení, Krajská nemocnice T. Bati, a. s., Univerzita Tomáše Bati ve Zlíně

- 1 Calda, P. – Břešťák, M. – Fischerová, D.: *Ultrazvuková diagnostika v těhotenství a gynekologii*. Aprofema, 2010, s. 459.
- 2 Kurman, R. J. – le-Ming Shih: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. *Shifting the paradigm, human Pathology*, 2012, 42, s. 918–931.
- 3 Eisenkop, S. – Spiro, N. M. – Friedman, R. L., et al.: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. *Gynecol Oncol*, 2003, 90, s. 390–396.
- 4 Zikán, M. – Cibula, D. – Fisherová, D., et al.: *Guideline gynekologických zhoubných nádorů: Standard – Komplexní léčba ovariálních epitelálních zhoubných nádorů*, www.onkogynekologie.com.

- 5 Engelen, M. J. – Kos, H. E. – Willemse, P. H., et al.: Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. *Cancer*, 2006, 106, s. 589–598.
- 6 Pignata, S. – Scambia, G. – Savarese, A., et al.: Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: Preliminary activity results of the MITO-2 phase III trial. *Oncology*, 2009, 76, s. 49–54.
- 7 Nový, F.: Antiangiogenní léčba ovariálního karcinomu. *Onkologie*, 2012, 6, www.onkologiecs.cz.
- 8 Chovanec, J.: Cílená biologická léčba karcinomu ovaria. *Praktická Gynecologie*, 2011, 15, s. 158–161.
- 9 Souhrn údajů o přípravku, Avastin 25 mg, dostupné z: www.medicines.org.uk/EMC/medicine/15748/SPC/Avastin, vyhledáno 29. 1. 2018.
- 10 Inman, S.: FDA Approves Olaparib Tablets for ovarian Cancer, dostupné z: onclive.com.
- 11 Souhrn studie ICON6, dostupné z: www.icon6.org.
- 12 Dinkic, C. – Eichbaum, M. – Schmidt, M., et al.: Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer – Results of the PACOVAR-trial. *Gynecologic Oncology*, 2017, 146, s. 279–284.
- 13 Polcher, M. – Eckhardt, M. – Coch, C., et al.: Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. *Cancer Chemother Pharmacol*, 2010, 66, s. 203–207.
- 14 Zweifel, G. C. – Jayson, N. S. – Reed, R., et al.: 211224 Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. *An Oncol*, 2011, 22, s. 2036–2041.
- 15 Podrazil, M. – Bartůňková, J.: Imunoterapie nádorových chorob. *Postgraduální medicína*, 19. 5. 2015.

Léčba metastatického karcinomu ledviny

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: *Epidemiologie zhoubných nádorů v České republice*. Masarykova univerzita, dostupné z: http://www.svod.cz. 2005, vyhledáno 25. 11. 2017.
- 2 Zhoubný novotvar ledviny (C64). *Modrá kniha České onkologické společnosti*. 23. aktualizace, Masarykův onkologický ústav, Brno. Platnost od 1. 3. 2017.
- 3 Motzer, R. J. – Bacik, J. – Murphy, B. A., et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J Clin Oncol*, 2002, 20, s. 289–296.
- 4 Heng, D. Y. C. – Xie, W. – Regan, M. M., et al.: External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol*, 2013, 14, s. 141–148.
- 5 Choueiri, T. K. – Escudier, B. – Powles, T., et al.: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 917–927.
- 6 Motzer, R. J. – Escudier, B. – McDermott, D. F., et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1803–1813.
- 7 Escudier, B. – Tannir, N. – McDermott, D. F.: *CheckMate 214: efficacy and safety of nivolumab plus ipilimumab (Nipi) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups*. Abstrakt LBA5, ESMO 2017.
- 8 Weber, J. S. – Postow, M. – Lao, C. D., et al.: Management of adverse events following treatment with anti-programmed death-1 agents. *Oncologist*, 2016, 21, s. 1230–1240.
- 9 Motzer, R. J. – Hutson, T. E. – Glen, H., et al.: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*, 2015, 16, s. 1473–1482.
- 10 Motzer, R. J. – Nosov, D. – Eisen, T., et al.: Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. *J Clin Oncol*, 2013, 31, s. 3791–3799.
- 11 Ljungberg, B. – Bensalah, K. – Canfield, S., et al.: EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol*, 2015, 67, s. 913–924.
- 12 Ravaud, A. – Motzer, R. J. – Pandha, H. S., et al.: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. *N Engl J Med*, 2016, 375, s. 2246–2254.
- 13 Haas, N. B. – Manola, J. – Uzzo, R. G., et al.: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet* (London, England), 2016, 387, s. 2008–2016.
- 14 Motzer, R. J. – Haas, N. B. – Donskov, F., et al.: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. *J Clin Oncol*, 2017, 35, s. 3916–3923.

Současné možnosti systémové léčby metastatického renálního karcinomu

MUDr. Ivo Kocák, Ph.D. | doc. MUDr. Ilona Kocáková, Ph.D.

Klinika komplexní onkologické péče Masarykova onkologického ústavu a LF MU, Brno

- 1 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2009, 27, s. 3584–3590.
- 2 Escudier, B. J. – Bellmunt, J. – Negrier, S., et al.: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab + interferon alfa 2a in metastatic renal cell carcinoma. *J Clin Oncol*, 2009, 27, abstrakt 5020.
- 3 Rini, B. I. – Halabi, S. W. – Rosenberg, J., et al.: Bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. *J Clin Oncol*, 2009, 27, abstrakt LBA5019.
- 4 Hudes, G. – Carducci, M. – Tomczak, P., et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 2271–2281.
- 5 Sternberg, C. N. – Davis, I. D. – Mardiyak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol*, 2010, 28, s. 1061–1068, Epub 25. 1. 2010.
- 6 Motzer, R. J. – Escudier, B. – Oudard, S., et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 2008, 372, s. 449–456.
- 7 Rini, B. I. – Escudier, B. – Tomczak, P.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*, 2011, 378, s. 1931–1939.
- 8 Choueiri, T. K. – Escudier, B. – Powles, T.: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 917–927.
- 9 Motzer, R. J. – Escudier, B. – McDermott, D. F.: Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1803–1813.
- 10 Motzer, R. J. – Hutson, T. E. – Glen, H.: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*, 2015, 16, s. 1473–1482.

Význam biomarkerů pro léčbu anti-VEGF inhibitory a její účinnost u metastatického kolorektálního karcinomu

MUDr. Zdeněk Linke Onkologická klinika FN v Motole, Praha

- 1 Grothey, A. – Van Cutsem, E. – Sobrero, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. *Lancet*, 2013, 381, s. 302–312.
- 2 Yoshino, T. – Mizunuma, N. – Yamazaki, K., et al.: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet*, 2012, 13, s. 993–1001.
- 3 Sartore-Bianchi, A. – Marsoni, S. – Siena, S.: Human epidermal growth factor receptor 2 as a molecular biomarker for metastatic colorectal cancer. *JAMA Oncol*, 2018, 4, s. 19–20.
- 4 Kopetz, S. – Desai, J. – Chan, E., et al.: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. *J Clin Oncol*, 2015, 33, s. 4032–4043.
- 5 Thurston, G. – Kitajewski, J.: VEGF and Delta-Notch: Interacting signalling pathway in tumor angiogenesis. *Br J Cancer*, 2008, 99, s. 1204–1209.
- 6 Qin, W. – Tao, L. – Zhigang, W., et al.: Novel VEGF decoy receptor fusion protein conbercept targeting multiple vegf isoforms provide remarkable anti-angiogenesis effect in vivo. *PLoS one*, doi.org/10.1371/journal.pone.0070544, 12. 8. 2013.
- 7 Bennouna, J. – Sastre, J. – Arnold, D., et al.: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet*, 2013, 14, s. 29–37.
- 8 Van Cutsem, E. – Tabernero, J. – Lakomy, R. – Prehn, H. – Prausova, J., et al.: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol*, 2012, 30, s. 3499–3506.
- 9 Tabernero, J. – Yoshino, T. – Lee Cohn, A., et al.: Ramucicromab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomized, double-blind, multicentre, phase 3 study. *Lancet*, 2015, 16, s. 499–508.
- 10 Ruff, P. – Ferry, D. R. – Lakomy, R., et al.: Aflibercept: a review in metastatic colorectal cancer. *ECJ*, 2015, 51, s. 18–26.
- 11 Wirapati, P. – Pomella, V. – Vandenbosch, B., et al.: Actualization of biomarkers in study VELOUR: Influence of RAS, BRAF and tumor location and efficacy of aflibercept. ASCO 2017, Gastrointestinal (Colorectal) Cancer poster session; abstrakt 3538.
- 12 Van Cutsem, E., et al.: *Ann Oncol Suppl*, 2017, WCGIC, abstrakt k přednášce, 29. 6. 2017.

Monoklonální protilátky anti-PD1 a anti-PD-L1 v léčbě solidních nádorů

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

- 1 Mittal, D. – Gubin, M. M. – Schreiber, R. D., et al.: New insights into cancer immunoevasion and its three component phases – elimination, equilibrium and escape. *Curr Opin Immunol*, 2014, 27, s. 16–25, doi: 10.1016/j.coi.2014.01.004, Epub 14. 2. 2014.
- 2 Domagala-Kulawik, J.: The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. *Transl Lung Cancer Res*, 2015, 4, s. 177–190.
- 3 Cogdill, A. P. – Andrews, M. C. – Wargo, J. A.: Hallmarks of response to immune check-point blockade. *Br J Cancer*, 2017, 117, s. 1–7, doi: 10.1038/bjc.2017.136, Epub 18. 5. 2017.
- 4 Borghaei, H. – Paz-Ares, L. – Horn, L., et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*,

- 2015, 373, s. 1627–1639, doi: 10.1056/NEJMoa1507643, Epub 27. 9. 2015.
- Massari, F. – Santoni, M. – Ciccarese, C., et al.: PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. *Cancer Treat Rev*, 2015, 41, s. 114–121, doi: 10.1016/j.ctrv.2014.12.013.
 - Shukuya, T. – Carbone, D. P.: Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. *J Thorac Oncol*, 2016, 11, s. 976–988, doi: 10.1016/j.jtho.2016.02.015, Epub 2. 5. 2016.
 - Subbiah, V. – Chuang, H. H. – Gambhire, D., et al.: Defining clinical response criteria and early response criteria for precision oncology: current state-of-the-art and future perspectives. *Diagnostics (Basel)*, 2017, 7, s. pii, E10, doi: 10.3390/diagnostics7010010.
 - Hodi, F. S. – O'Day, S. J. – McDermott, D. F., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*, 2010, 363, s. 711–723.
 - Lynch, T. J. – Bondarenko, I. – Luft, A., et al.: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol*, 2012, 30, s. 2046–2054.
 - Hao, C. – Tian, J. – Liu, H., et al.: Efficacy and safety of anti-PD-1 and anti-PD-L1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)*, 2017, 96, s. e7325, doi: 10.1097/MD.0000000000007325, recenze.
 - Comin-Anduix, B. – Escuin-Ordinas, H. – Ibarrodo, F. J.: Tremelimumab: research and clinical development. *Oncol Targets Ther*, 2016, 9, s. 1767–1776, doi: 10.2147/OTT.S65802.eCollection2016, recenze.
 - Chaudhari, P. B.: Nivolumab – pearls of evidence. *Indian J Med Paediatr Oncol*, 2017, 38, s. 520–525, doi: 10.4103/ijmpo.ijmpo_193_16, recenze.
 - Brahmer, J. – Reckamp, K. L. – Baas, P., et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.
 - Motzer, R. J. – Rini, B. I. – McDermott, D. F., et al.: Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. *J Clin Oncol*, 2015, 33, s. 1430–1437, doi: 10.1200/JCO.2014.59.0703.
 - Shanbhag, S. – Ambinder, R. F.: Hodgkin lymphoma: A review and update on recent progress. *Cancer J Clin*, 1. 12. 2017, doi: 10.3322/caac.21438, Epub před tiskem, recenze.
 - Karlsson, A. K. – Saleh, S. N.: Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. *Clin Cosmet Invest Dermatol*, 2017, 10, s. 325–339, doi: 10.2147/CCID.S120877.eCollection 2017.
 - Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer; KEYNOTE-024 Investigators. *N Engl J Med*, 2016, 375, s. 1823–1833, Epub 8. 10. 2016.
 - Yang, L. – Wang, L. – Zhang, Y.: Immunotherapy for lung cancer: advances and prospects. *Am J Clin Exp Immunol*, 2016, 5, s. 1–20.
 - Liang, F. – Zhu, J.: Pembrolizumab for advanced urothelial carcinoma. *N Engl J Med*, 2017, 376, s. 2302, doi: 10.1056/NEJMc1704612.
 - Rittmeyer, A. – Barlesi, F. – Waterkamp, D.; OAK Study Group et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*, 2017, 389, s. 255–265, doi: 10.1016/S0140-6736(16)32517-X, Epub 13. 12. 2016.
 - Bellmunt, J. – Powles, T. – Vogelzang, N. J.: A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. *Cancer Treat Rev*, 2017, 54, s. 58–67, doi: 10.1016/j.ctrv.2017.01.007, Epub 2. 2. 2017, recenze.
 - Kaufman, H. L. – Russell, J. S. – Hamid, O., et al.: Update efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. *J Immunother Cancer*, 2018, 6, s. 7, doi: 10.1186/s40425-017-0310-x.
 - Syed, Y. Y.: Durvalumab: first global approval. *Drugs*, 2017, 77, s. 1369–1376, doi: 10.1007/s40265-017-0782-5.
 - Antonia, S. J. – Villegas, A. – Daniel, D.; PACIFIC Investigators et al.: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 1919–1929, doi: 10.1056/NEJMoa1709937, Epub 8. 9. 2017.
 - De Velasco, G. – Je, Y. – Bossé, D., et al.: Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. *Cancer Immunol Res*, 2017, 5, s. 312–318, doi: 10.1158/2326-6066.CCR-16-0237, Epub 28. 2. 2017.

Metastazující melanom: možné léčebné strategie

MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika 1. LF UK a VFN, Praha

- Lang, B. M. – Oberhang-Paveling, A. – Faidt, D., et al.: Long-term survival with modern therapeutic agents against metastatic melanoma – vemurafenib and ipilimumab in daily life setting. *Medical Oncology*, 2018, 35, s. 24, DOI: org/10.1007/s12032-018-1084-9.
- Ives, N. J. – Suci, S. – Eggermont, A. M. M., et al.: Adjuvant Interferon alfa for the treatment of high risk melanoma: an individual patient data meta-analysis. *Eur J Cancer*, 2017, 82, s. 171–183.
- Eggermont, A. M. M. – Chiaro-Sileni, V. – Grob, J. J., et al.: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. *N Engl J Med*, 2016, 375, s. 1845–1855.
- Weber, J. – Mandala, M. – Del Vecchio, M., et al.: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med*, 2017, 377, s. 1824–1835.
- Lewis, K. – Maio, M. – Demidov, M., et al.: BRIM8 a randomized double blind placebo controlled study of adjuvant vemurafenib in patients with completely resected BRAF V600A melanoma at high risk for recurrence. *Ann Oncol*, 2017, 28, suppl. 5, mdx440.447.
- Long, G. V. – Hauschild, A. – Santinami, M., et al.: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Engl J Med*, 2017, DOI: 10.1056/NEJMoa1708539.
- Ascierto, A. P. – Palmieri, G. – Gogas, H.: What is changing in the adjuvant treatment of melanoma? *Oncotarget*, 2017, 8, s. 110735–110736.
- Robert, C. – Ribas, A. – Hamid, O., et al.: Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. *J Clin Oncol*, 2017, doi.org/10.1200/JCO.2017.75.6270.
- Turajlic, S. – Gore, M. – Larkin, J.: First report of overall survival for ipilimumab plus nivolumab from the Phase 3 Checkmate 067 study in advanced melanoma. *An Oncol*, mdy020, https://doi.org/10.1093/annonc/mdy020.
- Larkin, J. – Gonzales, R. – Thomas, L., et al.: Efficacy of nivolumab plus ipilimumab combination in patients with advanced melanoma and elevated serum lactate dehydrogenase: a pooled analysis. 9th World Congress of Melanoma, 2016, Brisbane.
- Flaherty, K. T. – Infante, J. R. – Daud, A., et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med*, 2012, 367, s. 1694–1703.
- Robert, C. – Karaszewska, B. – Schachter, J., et al.: Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K mutant cutaneous melanoma. *Ann Oncol*, 2016, 27, suppl. 6, s. 552–587.
- Ascierto, P. A. – McArthur, G. A. – Dreno, B., et al.: Cobimetinib combined with vemurafenib in advanced BRAF V600 mutant melanoma (coBRIM): updated efficacy and results from a randomized, double blind phase 3 trial. *Lancet Oncol*, 2016, 17, s. 1248–1260.
- Long, G. V. – Flaherty, K. T. – Stroyakovskiy, D., et al.: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K mutant melanoma: long term survival and safety Analysis of a phase 3 study. *An Oncol*, 2017, 28, s. 1631–1639.
- Johnson, D. B. – Flaherty, K. T. – Weber, J. S., et al.: Combined BRAF (dabrafenib) and MEK (trametinib) inhibition in patients with BRAF V600 mutant melanoma experiencing progression with single agent BRAF inhibitor. *J Clin Oncol*, 2014, 32, s. 3697–3704.
- Gibney, G. T. – Atkins, M. B.: Immunotherapy or molecular targeted therapy: what is the best initial treatment for stage IV BRAF mutant melanoma? *Clin Adv Hematol Oncol*, 2015, 13, s. 451–458.
- Dummer, R. – Hauschild, A. – Lindemann, N., et al.: Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow up. *Ann Oncol*, 2015, suppl. 5, s. 126–132.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: melanoma, 2016.

Minimizace rizik spojených s biologickou léčbou roztroušené sklerózy

MUDr. Radek Ampapa Centrum pro léčbu demyelinizačních onemocnění, Neurologické oddělení Nemocnice Jihlava

- Frohman, E. M. – Racek, M. K. – Raine, C. S.: Multiple sclerosis – the plaque and its pathogenesis. *N Engl J Med*, 2006, 354, s. 942–955.
- Ciriaco, M. – Venrice, P. – Russo, G. – Scicchitano, M., et al.: Corticosteroid-related central nervous system side effects. *J Pharmacol Pharmacother*, 2013, 4, suppl. 1, s. S94–S98.
- Moses, H. Jr. – Brandes, D. W.: Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. *Curr Med Res Opin*, 2008, 24, s. 2679–2690.
- Lebrun, C. – Bertagna, M. – Cohen, M.: Cutaneous side-effects of immunomodulators in MS. *Int MS J*, 2011, 17, s. 88–94.
- Jiwon, O. – O'Connor, P. W.: Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. *Ther Adv Neurol Disord*, 2014, 7, s. 239–252.
- Assessment report – Tysabri. European Medicines Agency, 11. 2. 2016, EMA/PRAC/171485/2016. Pharmacovigilance Risk Assessment Committee (PRAC).
- Laroni, A. – Brogi, D. – Brescia Morra, V., et al.: Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. *Neurol Sci*, 2017, 38, s. 53–59.
- Fox, R. J. – Kita, M. – Cohan, S. L., et al.: BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. *Curr Med Res Opin*, 2014, 30, s. 251–262.
- Tuohy, O. – Costelloe, L. – Hill-Cawthorne, G., et al.: Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. *J Neurol Neurosurg Psychiatry*, 2015, 86, s. 208–215, doi: 10.1136/jnnp-2014-307721, Epub 21. 5. 2014.
- Hauser, S. L. – Comi, G. C. – Hartung, H. P., et al.: Efficacy and safety of ocrelizumab in relapsing multiple sclerosis – results of the interferon-beta-1a-controlled, double-blind, Phase III OPERA I and II studies. (Abstract release date: Sep 23, 2015) *ECTRIMS Online Library*, 9. 10. 2015; 116634.
- Montalban, X. – Hemmer, B. – Rammohan, K., et al.: Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis – results of placebo-controlled, double-blind, Phase III ORATORIO study. *ECTRIMS*, 10. 10. 2015; 116701
- Giovannoni, G.: Cladribine to treat relapsing forms of multiple sclerosis. *Neurotherapeutics*, 2017, 14, s. 874–887.
- Giovannoni, G. – Soelberg Sorensen, P. – Cook, S., et al.: Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. *Mult Scler*, 1. 8. 2017, 1352458517727603.
- Registr ReMuS – Souhrnná zpráva z registru k 30. 6. 2017. Dostupné z: http://nfmimpuls.cz/images/docs/remus_zaverecne-zpravy/ReMuS_zaverecna-zprava_2017_06_souhrnna_v2.pdf, vyhledáno 29. 1. 2018.

Biologická léčba v neurologii

doc. MUDr. Martin Vališ, Ph.D. | MUDr. Zbyšek Pavelk Neurologická klinika LF a FN Hradec Králové

- Steinman, L.: Multiple sclerosis: a two-stage disease. *Nature Immunol*, 2001, 2, s. 762–764.
- Salzer, J. – Hallmans, G. – Nyström, M., et al.: Vitamin D as a protective factor in multiple sclerosis. *Neurology*, 2012, 79, s. 2140–2145.
- Pohl, D. – Krone, K. – Rostasy, K., et al.: High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. *Neurology*, 2006, 67, s. 2063–2065.
- Holick, F. M.: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr*, 2004, 80, s. 1678S–1688S.
- Hindorf, L. A. – Sethupathy, P. – Junktins, H. A., et al.: Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A*, 2009, 106, s. 9362–9367.
- Matesanz, F. – González-Pérez, A. – Lucas, M., et al.: Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. *PLoS One*, 2012, 7, s. e36140.
- International Multiple Sclerosis Genetics Consortium: A high-density screen for linkage in multiple sclerosis. *Am J Hum Genet*, 2005, 77, s. 454–467.
- Pavelka, K. – Arenberger, P. – Lukáš, M., et al.: Biologická léčba

- zánětlivých autoimunitních onemocnění.* Grada, 2014, s. 17–21.
- 9 Vališ, M. – Pavelek, Z.: Roztroušená skleróza – eskalace léčby a medicína založená na důkazech. *Neurol praxi*, 2017, 18, suppl. F.
 - 10 Anderton, S. M. – Liblau, R. S.: Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. *Curr Opin Neurol*, 2008, 21, s. 248–254.
 - 11 Chabot, S. – Williams, G. – Yong, V. W.: Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferon-beta-1b. *J Clin Invest*, 1997, 100, s. 604–612.
 - 12 Chen, M. – Chen, G. – Nie, H., et al.: Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. *Eur J Immunol*, 2009, 39, s. 2525–2536, doi: 10.1002/eji.200838879.
 - 13 Markowitz, C. E.: Interferon-beta: mechanism of action and dosing issues. *Neurology*, 2007, 68, suppl. 4, s. S8–11.
 - 14 Aharoni, R. – Schlegel, P. G. – Teitelbaum, D., et al.: Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. *Immunol Lett*, 1997, 58, s. 79–87.
 - 15 Ziemssen, T. – Schrempf, W.: Glatiramer acetate: mechanisms of action in multiple sclerosis. *Int Rev Neurobiol*, 2007, 79, s. 537–570.
 - 16 Gold, R. – Wolinsky, J. S.: Pathophysiology of multiple sclerosis and the place of teriflunomide. *Acta Neurol Scand*, 2011, 124, s. 75–84.
 - 17 Scannevin, R. H. – Chollate, S. – Jung, M. Y., et al.: Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. *J Pharmacol Exp Ther*, 2012, 341, s. 274–284.
 - 18 Linker, R. A. – Lee, D. H. – Ryan, S., et al.: Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain*, 2011, 134, s. 678–692.
 - 19 Wang, Q. – Chuikov, S. – Taitano, S., et al.: Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway. *Int J Mol Sci*, 2015, 16, s. 13885–13907.
 - 20 Schulze-Topphoff, U. – Varrin Doyer, M. – Pekarek, R., et al.: Dimethyl fumarate utilizes Nrf2-independent and Nrf2 dependent pathways for immunomodulation. *Neurology*, 2014, 82, suppl., abstrakt S53.002.
 - 21 Albrecht, P. – Bouchachia, I. – Goebels, N., et al.: Effects of dimethyl fumarate on neuroprotection and immunomodulation. *J Neuroinflammation*, 2012, 9, s. 163.
 - 22 Parodi, B. – Rossi, S. – Morando, S., et al.: Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. *Acta Neuropathol*, 2015, 130, s. 279–295.
 - 23 Chun, J. – Hartung, H. P.: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. *Clin Neuropharmacol*, 2010, 33, s. 91–101.
 - 24 Brinkmann, V. – Billich, A. – Baumruker, T., et al.: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. *Nat Rev Drug Discov*, 2010, 9, s. 883–897, doi: 10.1038/nrd3248.
 - 25 Rudick, R. A. – Sandrock, A.: Natalizumab: alpha4-integrin antagonist selective adhesion molecule inhibitors for MS. *Expert Rev Neurotherapeutics*, 2004, 4, s. 571–580.
 - 26 Freedman, M. S. – Kaplan, J. M. – Markovic-Plese, S.: Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. *J Clin Cell Immunol*, 2013, 4, s. 1–9.
 - 27 Havari, E. – Turner, M. J. – Campos-Ribera, J., et al.: Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. *Immunology*, 2014, 141, s. 123–131.
 - 28 Comi, G. – De Stefano, N. – Freedman, M. S.: Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. *Lancet Neurol*, 2012, 11, s. 33–41.
 - 29 Jacobs, L. – Beck, R. W. – Simon, J. H., et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. *N Engl J Med*, 2000, 343, s. 898–904.
 - 30 Kappos, L. – Freedman, M. S. – Polman, C. H., et al.: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. *Lancet*, 2007, 370, s. 389–397.
 - 31 Comi, G. – Martinelli, V. – Rodegher, M., et al.: Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCIS study): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2009, 374, s. 1503–1511, doi: 10.1016/S0140-6736(09)61259-9.
 - 32 Miller, A. E. – Wolinsky, J. S. – Kappos, L., et al.: Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol*, 2014, 13, s. 977–986, doi: 10.1016/S1474-4422(14)70191-7, Epub 2.9.2014.
 - 33 Gold, R. – Kappos, L. – Arnold, D. L., et al.: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med*, 2012, 367, s. 1098–1107.
 - 34 Fox, R. J. – Miller, D. H. – Phillips, J. T., et al.: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *N Engl J Med*, 2012, 367, s. 1087–1097.
 - 35 Cohen, J. A. – Barkhof, F. – Comi, G., et al.: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 402–415.
 - 36 Kappos, L. – Radue, E. W. – O'Connor, P., et al.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 387–401.
 - 37 Polman, C. H. – O'Connor, P. W. – Havrdova, E., et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*, 2006, 354, s. 899–910.
 - 38 Cohen, J. A. – Coles, A. J. – Arnold, D. L., et al.: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet*, 2012, *Neurology*, 2014, 82, suppl. P2.199; 380, s. 1819–1828.
 - 39 Coles, A. J. – Twyman, C. L. – Arnold, D. L., et al.: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet*, 2012, 380, s. 1829–1839.
 - 40 Khan, S. – Olesen, A. – Ashina, M.: CGRP: a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. *Cephalalgia*, 1. 1. 2017, doi:10.1177/0333102417741297.

Léčba axiálních spondyloartritid k cíli (koncept T2T)

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 van der Heijde, D. – Dijkman, B. – Geusens, P., et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum*, 2005, 52, s. 582–591.
- 2 Sieper, J. – van der Heijde, D. – Dougados, M.: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised, placebo controlled trial (ABILITY-1). *Ann Rheum Dis*, 2013, 72, s. 815–822.
- 3 Sieper, J. – Lenaerts, J. – Wollenhaupt, J.: Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. *Ann Rheum Dis*, 2014, 73, s. 101–107.
- 4 Braun, J. – van der Horst-Bruinsma, I. E. – Huang, F., et al.: Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: a randomized double blind study (ASCEND Trial). *Arthritis Rheum Online*, 10. 1. 2011, doi: 10.1002/art.30223.
- 5 Landewé, R. – Braun, J. – Deodhar, A., et al.: Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis*, 2014, 73, s. 39–47, doi: 10.1136/annrheumdis-2013-204231, Epub 6. 9. 2013.
- 6 Inman, R. D. – Davis, J. C. Jr. – van der Heijde, et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum*, 2008, 58, s. 3402–3412.
- 7 Sieper, J. – Deodhar, A. – Marzo-Ortega, H., et al.: Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. *Ann Rheum Dis*, 2016, dostupné z: <http://dx.doi.org/10.1136/annrheumdis-2016-210023>, vyhledáno 6. 2. 2018.
- 8 Solomon, D. H. – Losina, E. – Lu, B., et al.: Implementation of treat-to-target in rheumatoid arthritis through a learning collaborative: results of a randomized controlled trial. *Arthritis Rheumatol*, 2017, Epub před tiskem.
- 9 Coates, L. C. – Moverley, A. R. – McParland, L., et al.: Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet*, 2015, 386, s. 2489–2498.
- 10 Smolen, J. S. – Braun, J. – Dougados, M., et al.: Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Ann Rheum Dis*, 2014, 73, s. 6–16.
- 11 Vermeer, M. – Kuper, H. H. – Bernelot Moens, H. J., et al.: Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. *Arthritis Res Ther*, 2012, 14, s. R254.
- 12 Garrett, S. – Jenkinson, T. – Kennedy, L. G., et al.: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol*, 1994, 21, s. 2286–2291.
- 13 Machado, P. – Landewé, R. – Lie, E., et al.: Ankylosing Spondylitis Disease Activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis*, 2011, 70, s. 47–53.
- 14 Poddubnyy, D. – Protodopov, M. – Haibel, H., et al.: High disease activity according to the Ankylosing Spondylitis Disease Activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Ann Rheum Dis*, 2016, 72, s. 2114–2118.
- 15 Coates, L. C. – Fransen, J. – Helliwell, P. S.: Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Ann Rheum Dis*, 2010, 69, s. 48–53.
- 16 Van der Heijde, D., et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum*, 2016, 68, suppl. 10.
- 17 Pavelka, K. – Vencovský, J. – Šenolt, L., et al.: *Farmakoterapie revmatických onemocnění*. Maxdorf/Jessenius, Praha, 2017.
- 18 Smolen, J., et al.: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis*, 2018, 77, s. 3–17.

Riziko nádorové choroby při léčbě konvenčními, cílenými a biologickými DMARDs u pacientů s revmatoidní artritidou

MUDr. Šárka Forejtová Revmatologický ústav, Praha

- 1 Franklin, J. – Lunt, M. – Bunn, D., et al.: Influence of inflammatory polyarthritis on cancer incidence and survival: results from community-based prospective study. *Arthritis Rheum*, 2007, 56, s. 790–798.
- 2 Dougados, M.: Comorbidities in rheumatoid arthritis. *Curr Opin Rheumatol*, 2016, 28, s. 282–288.
- 3 Asklung, J. – Foreed, C. M. – Brandt, L., et al.: Risk of solid cancers in patients with rheumatoid arthritis and following treatment with tumor necrosis factor antagonists. *Ann Rheum Dis*, 2005, 64, s. 1421–1426.
- 4 Thomas, E. – Brewster, D. H. – Black, R. J., et al.: Risk of malignancy among patients with rheumatic conditions. *Int J Cancer*, 2000, 88, s. 497–502.
- 5 Smitten, A. L. – Simon, T. A. – Hochberger, M. C., et al.: A meta-analysis of incidence of malignancy in adult patients with rheumatoid arthritis. *Arthritis Research & Therapy*, 2008, 10, R45.
- 6 Simon, T. A. – Thompson, A. – Gandhi, K. K., et al.: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Research & Therapy*, 2015, 15, s. 212.
- 7 Baecklund, E. – Illiadou, A. – Asklung, L., et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum*, 2006, 54, s. 692–701.
- 8 Matteson, E. L. – Hickey, A. R. – Maguire, L., et al.: Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in DMARDs Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. *J Rheumatol*, 1991, 18, s. 809–814.
- 9 Buchbinder, R. – Barber, M. – Heuzenroeder, L., et al.: Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum*, 2008, 59, s. 794–797.
- 10 Bachman, T. R. – Sawitzke, A. D. – Perkins, S., et al.: Methotrexate-associated lymphoma in patients with rheumatoid arthritis. *Arthritis Rheum*, 1996, 39, s. 325–329.
- 11 Miyazaki, T. – Fujimaki, K. – Shirasugi, Y., et al.: Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. *Am J Hematol*, 2007, 82, s. 1106–1109.
- 12 Hoshida, Y. – Xu, J. X. – Fujita, S., et al.: Lymphoproliferative disorders

- in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. *J Rheumatol*, 2007, 34, s. 322–331.
- 13 Raheel, S. – Crowson, C. S. – Wright, K., et al.: Risk of malignant neoplasms in patients with incident rheumatoid arthritis 1980–2007 in relation to a comparator cohort: a population-based study. *Int J Rheumatol*, 2016, ID 4609486.
 - 14 Wolfe, F. – Michaud, K.: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. *Arthritis Rheum*, 2004, 50, s. 1740–1751.
 - 15 Fiorentino, D. – Ho, V. – Lebowitz, M. G., et al.: Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. *J Am Acad Dermatol*, 2017, 77, s. 845–854.
 - 16 Mariette, X. – Cozals-Hetam, D. – Warszawski, K., et al.: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. *Blood*, 2002, 99, s. 3909–3915.
 - 17 Mercer, L. K. – Davies, R. – Galloway, J. B., et al.: Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. *Rheumatology (Oxford)*, 2013, 52, s. 91–98.
 - 18 Smedby, K. E. – Baecklund, E. – Asklung, J.: Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. *Cancer Epidemiol Biomarkers Prev*, 2006, 15, s. 2069–2077.
 - 19 Wilton, K. M. – Matteson, E. L.: Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. *Rheumatol Ther*, 2017, 4, s. 333–347.
 - 20 Polesie, G. – Gillstedt, M. – Sönnergen, H. H., et al.: Methotrexate treatment and risk of cutaneous malignant melanoma: a retrospective comparative registry-based cohort study. *Br J Dermatol*, 2017, 176, s. 1492–1499.
 - 21 Jiang, L. – Zhang, W. – Li, W., et al.: Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro. *Toxicol Lett*, 2018, 282, s. 154–165.
 - 22 Baumann, P. – Mandl-Weber, S. – Volk, A., et al.: Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. *Mol Cancer Ther*, 2009, 8, s. 366–375.
 - 23 Alhefdhi, A. – Burke, J. F. – Redlich, A., et al.: Leflunomide suppresses growth in human medullary thyroid cancer cells. *J Surg Res*, 2013, 185, s. 212–216.
 - 24 Strangfeld, A. – Hydrich, K. – Asklung, J., et al.: Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. *Rheumatology (Oxford)*, 2011, 50, s. 146–151.
 - 25 Silman, A. J. – Petrie, J. – Hazleman, B., et al.: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated in azathioprine: a 20 year follow up study. *Ann Rheum Dis*, 1988, 47, s. 988–992.
 - 26 Bernatsky, S. – Clarke, A. E. – Suissa, S.: Hematologic malignant neoplasm after drug exposure in rheumatoid arthritis. *Arch Intern Med*, 2008, 168, s. 378–381.
 - 27 Radis, C. D. – Kahl, L. E. – Baker, G. L., et al.: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. *Arthritis Rheum*, 1995, 38, s. 1120–1127.
 - 28 Asten, P. – Barret, J. – Symmons, D.: Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. *J Rheumatol*, 1999, 26, s. 1705–1714.
 - 29 Cohen, S. B. – Tanaka, Y. – Mariette, X., et al.: Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. *Ann Rheum Dis*, 2017, 76, s. 1253–1262.
 - 30 Cohen, S. – Curtis, J. R. – DeMasi, R., et al.: Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. *Rheumatol Ther*, 2018, publikováno online.
 - 31 Smolen, J. S. – Genovese, M. C. – Takeuchi, T., et al.: Safety profile of baricitinib in patients with active rheumatoid arthritis: an integrated analysis. Prezentováno jako poster na European League Against Rheumatism (EULAR) Annual Meeting, 8.–11. 6. 2016, Londýn, Velká Británie.
 - 32 Keystone, E. C. – Genovese, M. C. – Schlichting, D. E., et al.: Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. *J Rheumatol*, 2018, 45, s. 14–21.
 - 33 Bongartz, T. – Sutton, A. J. – Seeting, M. J., et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA*, 2006, 295, s. 2275–2285.
 - 34 Bongartz, T. – Warren, F. C. – Mines, D., et al.: Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systemic review and individual patient data meta-analysis of randomized controlled trials. *Ann Rheum Dis*, 2009, 68, s. 1177–1183.
 - 35 Mercer, L. K. – Lunt, M. – Low, A. L., et al.: Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. *Ann Rheum Dis*, 2015, 74, s. 1087–1093.
 - 36 Ramiro, S. – Gaujoux-Viala, C. – Nam, J. L., et al.: Safety of synthetic and biological DMARDs: a systemic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis*, 2014, 73, s. 529–535.
 - 37 Solomon, D. H. – Kremer, J. M. – Fisher, M., et al.: Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. *Semin Arthritis Rheum*, 2014, 43, s. 489–497.
 - 38 Michaud, T. L. – Rho, Y. A. – Shamliyan, T., et al.: The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. *Am J Med*, 2014, 127, s. 1208–1232.
 - 39 Mariette, X. – Matucci-Cerinic, M. – Pavelka, K., et al.: Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis. *Ann Rheum Dis*, 2011, 70, s. 1895–1904.
 - 40 Asklung, J. – Fahrback, K. – Nordstrom, R., et al.: Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. *Pharmacoepidemiol Drug Saf*, 2011, 20, s. 119–130.
 - 41 Mercer, L. K. – Asklung, J. – Raaschau, P., et al.: Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from collaborative project of 11 European Biological Registers. *Ann Rheum Dis*, 2017, 76, s. 386–391.
 - 42 Dreyer, L. – Mellemkjaer, L. – Andersen, A. R., et al.: Incidences of overall and site specific cancer in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow up study from the DANBIO Registry. *Ann Rheum Dis*, 2013, 72, s. 79–82.
 - 43 Buchbinder, R. – Van Doornum, S. – Staples, M., et al.: Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumor necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study. *BMS Musculoskeletal Disord*, 2015, 20, s. 309.
 - 44 Lan, J. L. – Tseng, C. H. – Chen, J. H., et al.: Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNFalpha inhibitor. *Medicine (Baltimore)*, 2017, 96, s. e6055.
 - 45 Nanau, R. M. – Neuman, M. G.: Safety of anti-tumor necrosis factor therapies in arthritis patients. *J Pharm Sci*, 2014, 17, s. 324–361.
 - 46 Asklung, J. – Baecklund, E. – Granath, E., et al.: Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risk and time trends in the Swedish Biologic Register. *Ann Rheum Dis*, 2009, 68, s. 648–653.
 - 47 Lebre, H. – Ponce, R. – Preston, B. D., et al.: Tumor necrosis factor, tumor necrosis factor inhibition and cancer risk. *Curr Med Res Opin*, 2015, 31, s. 557–574.
 - 48 Mercer, L. K. – Galloway, J. B. – Lunt, M., et al.: Risk of lymphoma in patients exposed to anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologic Register for Rheumatoid Arthritis. *Ann Rheum Dis*, 2017, 76, s. 497–503.
 - 49 Baecklund, E. – Ekblom, A. – Sparen, P., et al.: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. *BMJ*, 1998, 317, s. 180–181.
 - 50 Niitsu, N. – Okamoto, M. – Nakamine, H., et al.: Clinicopathological correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. *Cancer Sci*, 2010, 101, s. 1309–1313.
 - 51 Yamamoto, K. – Goto, H. – Hiraio, K., et al.: Long-term safety of tocilizumab: results from 3 years of follow-up postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. *J Rheumatol*, 2015, 42, s. 1368–1375.
 - 52 Schiff, M. H. – Kremer, J. M. – Jahreis, A., et al.: Integrated safety in tocilizumab clinical trials. *Arthritis Res Ther*, 2011, 13, s. 141.
 - 53 Raaschau, P. – Simard, J. F. – Neovius, M., et al.: Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. *Arthritis Rheum*, 2011, 63, s. 1812–1822.
 - 54 Wadström, H. – Frisell, T. – Asklung, J.: Malignant neoplasm in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept or rituximab in clinical practice. A nationwide cohort study from Sweden. *JAMA*, 2017, 177, s. 1605–1612.
 - 55 Dixon, W. G. – Watson, K. D. – Lunt, M., et al.: Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: a results from the British Society for Rheumatology Biologic Register. *Arthritis Care Res (Hoboken)*, 2010, 62, s. 755–763.
 - 56 Raaschau, P. – Frisell, T. – Asklung, J., et al.: TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. *Ann Rheum Dis*, 2015, 74, s. 2137–2143.
 - 57 Mantani, R. – Clark, A. S. – Scott, F. I., et al.: Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. *Arthritis Rheum*, 2016, 68, s. 2403–2411.
 - 58 Mercer, L. K. – Low, A. S. – Galloway, J. B., et al.: Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. *Ann Rheum Dis*, 2013, 72, s. 143–144.
 - 59 Shelton, E. – Lahaie, D. – Scott, F. I., et al.: Cancer recurrence following immune-suppressive therapies in patients with immune-mediated disease: a systemic review and meta-analysis. *Gastroenterology*, 2016, 15, s. 97–104.
 - 60 Silva-Fernández, L. – Lunt, M. – Kaersley-Fleet, L., et al.: The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. *Rheumatology*, 2016, 55, s. 2033–2039.
 - 61 Abasolo, L. – Judez, E. – Descalzo, M. A., et al.: Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. *Semin Arthritis Rheum*, 2008, 37, s. 388–397.
 - 62 Ji, J. – Liu, X. – Sundquist, K. – Sundquist, J.: Survival of cancer in patients with rheumatoid arthritis: a following-up study in Sweden of patients hospitalised with rheumatoid arthritis 1 year before diagnosis of cancer. *Rheumatology (Oxford)*, 2011, 50, s. 1513–1518.
 - 63 Nayak, P. – Luo, R. – Elzing, L., et al.: Impact of rheumatoid arthritis on the mortality of elderly patients who develop cancer: a population-based study. *Arthritis Care Res (Hoboken)*, 2017, 69, s. 75–83.
 - 64 Thomas, E. – Symmons, D. P. – Brewster, D. H., et al.: National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow-up study. *J Rheumatol*, 2003, 30, s. 958–965.
 - 65 Hashimoto, A. – Chiba, N. – Tsuno, H., et al.: Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to general population. *J Rheumatol*, 2015, 42, s. 564–571.
 - 66 Shen, K. – Xu, G. – Wu, Q., et al.: Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies. *PLoS ONE*, 2014, 9, s. e91461.

Subkutánní tocilizumab v terapii revmatoidní artritidy

MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- 1 Scott, D. L. – Wolfe, F. – Huizinga, T. W.: Rheumatoid arthritis. *Lancet*, 2010, 376, s. 1094–1108.
- 2 Tugwell, P. – Singh, J. A. – Wells, G. A.: Biologics for rheumatoid arthritis. *BMJ*, 2011, 343, d4027.
- 3 Ioannidis, J. P. – Karassa, F. B. – Druyts, E., et al.: Biologic agents in rheumatology: unmet issues after 200 trials and \$200 billion sales. *Nature Reviews Rheumatology*, 2013, 9, s. 665–673.
- 4 Gabay, C. – Emery, P. – van Vollenhoven, R., et al.: ADACTA Study Investigators: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet*, 2013, 4, 381, s. 1541–1550.
- 5 Alonso, R. B. – Bilbao, M. A.: Inhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis. *Reumatol Clin*, 2009, 5, s. 121–127.
- 6 Kim, S. – Östör, A. J. – Nisar, M. K.: Interleukin-6 and cytochrome-P450, reason for concern? *Rheumatol Int*, 2012, 32, s. 2601–2604.
- 7 Souhm údajů o přípravku RoActemra, dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/000955/WC500054890.pdf, vyhledáno 14. 2. 2018.
- 8 Nishimoto, N. – Kishimoto, T.: Humanized anti-human IL-6 receptor antibody, tocilizumab. *Handb Exp Pharmacol*, 2008, 181, s. 151–160.
- 9 Yazici, Y. – Curtis, J. R. – Ince, A., et al.: Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. *Ann Rheum Dis*, 2012, 71, s. 198–205.
- 10 Yazici, Y. – Curtis, J. R. – Ince, A., et al.: Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). *Clin Exp Rheumatol*, 2013, 31, s. 358–364.
- 11 Genovese, M. C. – McKay, J. D. – Nasonov, E. L., et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum*, 2008, 58, s. 2968–2980.
- 12 Maini, R. N. – Taylor, P. C. – Szechinski, J., et al.: CHARISMA Study Group: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum*, 2006, 54, s. 2817–2829.

- 13 Smolen, J. S. – Beaulieu, A. – Rubbert-Roth, A., et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet*, 2008, 371, s. 987–997.
- 14 Bay-Jensen, A. C. – Platt, A. – Byrjalsen, I., et al.: Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. *Semin Arthritis Rheum*, 2014, 43, s. 470–478.
- 15 Fleischmann, R. M. – Halland, A. M. – Brzosko, M., et al.: Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. *J Rheumatol*, 2013, 40, s. 113–126.
- 16 Nishimoto, N. – Miyasaka, N. – Yamamoto, K., et al.: Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Mod Rheumatol*, 2009, 19, s. 12–19.
- 17 Nishimoto, N. – Hashimoto, J. – Miyasaka, N., et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURA): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis*, 2007, 66, s. 1162–1167.
- 18 Kivitz, A. – Olech, E. – Borofsky, M., et al.: Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. *Arthritis Care & Research*, 2014, 66, s. 1653–1661.
- 19 Ogata, A. – Tanimura, K. – Sugimoto, T., et al.; Musashi Study Investigators: Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken)*, 2014, 66, s. 344–354.
- 20 Burmester, G. R. – Rubbert-Roth, A. – Cantagrel, A., et al.: A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). *Ann Rheum Dis*, 2014, 73, s. 69–74.
- 21 Choy, E. – Caporali, R. – Xavier, R., et al.: Subcutaneous tocilizumab monotherapy or combined with a csDMARD in patients with rheumatoid arthritis: TOZURA, a pooled analysis of phase IV studies in 22 countries [abstract no. Sat0199]. *Ann Rheum Dis*, 2017, 76, suppl. 2, s. 847–848.

Reslizumab – nová zbraň v boji s těžkým refrakterním eozinofilním astmatem

MUDr. Vratislav Sedlák, Ph.D. Plicní klinika FN Hradec Králové a LF UK, Hradec Králové

- 1 Bateman, E.: GINA – Global Initiative for Asthma Document, 2011.
- 2 Teif, M., et al.: *Doporučený postup diagnostiky a léčby bronchiálního astmatu*. GEUM, Semily, 2015.
- 3 Sedlák, V. – Kudela, O. – Koblížek, V.: Problematiké těžké asthma bronchiale. *Acta Medicinæ*, 2014, 3, s. 52–58.
- 4 Bel, E. H. – Sousa, A. – Flemming, L., et al.; on behalf of the members of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation: Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). *Thorax*, 2011, 66, s. 910–917.
- 5 Moore, C. W. – Meyers, D. A. – Wenzel, S. E., et al.: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med*, 2010, 181, s. 315–323.
- 6 The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. *Eur Respir J*, 2003, 22, s. 470–477.
- 7 Humbert, M. – Beasley, R. – Ayres, J., et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy*, 2005, 60, s. 309–316.
- 8 Leckie, M. – ten Brinke, A. – Khan, J., et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet*, 2000, 356, s. 2144–2148.
- 9 Varrachi, G. – Bagnasco, D. – Borriello, F., et al.: Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. *Curr Opin Allergy Clin Immunol*, 2016, 16, s. 186–200.
- 10 Castro, M. – Mathur, S. – Hargreave, F., et al.: Reslizumab for poorly controlled, eosinophilic asthma, a randomized, placebo controlled study. *Am J Respir Crit Care Med*, 2011, 184, s. 1125–1132.
- 11 Castro, M. – Zangrilli, J. – Wechsler, M. E., et al.: Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med*, 2015, 3, s. 355–366.
- 12 Brusselle, G. – Germinaro, M. – Weiss, S., et al.: Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. *Pulm Pharm Ther*, 2017, 47, s. 39–45.
- 13 Brussele, G. – Canvin, J. – Weiss, S., et al.: Stratification of eosinophilic asthma patients treated with reslizumab and GINA 4 or 5 therapy. *ERJ Open Res*, 2017, 3, pii: 00004–2017, doi: 10.1183/23120541.00004-2017.

Studie I-SPY 2: patologická kompletní odpověď v léčbě karcinomu prsu predikuje přežití bez relapsu a bez distanční recidivy

MUDr. Iveta Kolářová, Ph.D. | doc. MUDr. Jaroslav Vaňásek, CSc. | MUDr. Aleš Hlávka

Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o.

MUDr. Jana Mergancová Chirurgická klinika, Nemocnice Pardubického kraje, a. s., Pardubická nemocnice

- 1 Das, S. – Lo, A. W.: Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program. *Contemporary clinical trials*, 2017, 62, s. 168–174.
- 2 Hay, M. – Thomas, D. W. – Craighead, J. L., et al.: Clinical development access rates for investigational drugs. *Nature Biotechnology*, 2014, 32, s. 40.
- 3 Cortazar, P. – Zhang, L. – Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- 4 de Lartigue, J.: A look at I-SPY 2: novel trial design may expand the scope of oncology drug development, 2014. Dostupné z: <http://www.onclive.com/publications/oncology-live/2014/march-2014/a-look-at-i-spy-2-novel-trial-design-may-expand-the-scope-of-oncology-drug-development?p=4>, vyhledáno 5. 3. 2018.
- 5 Yee, D. – DeMichele, A. – Isaacs, C., et al.: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY 2 trial. 2017 San Antonio Breast Cancer Symposium, abstrakt G53-08, prezentováno v 7. 12. 2017.